I obtained my PhD from Johns Hopkins University School of Medicine, studying Frizzled signaling in retinal angiogenesis and kidney development with Jeremy Nathans. I then trained with Bob Weinberg as a postdoctoral fellow at Whitehead Institute/MIT. Using mouse genetic approaches, my work uncovered distinct roles of SLUG vs SNAIL EMT transcription factors in normal mammary stem cells versus breast cancer stem cells.
I joined the Department of Discovery Oncology as a scientist in 2017. My group is interested in developing new technologies and methods to dissect pre-existing and adaptive programs associated with responses versus resistance to targeted therapies. We hope such knowledge will facilitate our drug discovery efforts and rational designs of drug combinations.
Postdocs bring fresh ideas to our research community and the postdoc program provides groups like mine a valuable opportunity to pursue important research questions related to our drug targets. I am honored to be part of this top-class program and look forward to mentoring future generations of scientists and growing my science with them.
Nature Biotechnology; 2021
Targeted therapies have demonstrated significant clinical benefits in many cancer patients. We believe that a deep understanding of the mechanisms underlying therapeutic responses versus resistance will spur the development of newer therapeutic approaches. We are particularly interested in dissecting the pre-existing and adaptive transcriptional programs that drive therapy resistance by leveraging and developing single cell and genomics approaches.